The committee was told that no unexpected adverse effects occurred with Busulfex in the clinical trials. All adverse effects reported were consistent with those in patients receiving oral busulfan, and occurred as a consequence of myelosuppression and progenitor cell transplantation. Bone marrow or blood stem cell transplant is the treatment of choice for a variety of diseases not treatable with conventional therapy, offering a potential for cure in some patients. These diseases include leukemias, hemotologic malignancies and certain non-hemotologic malignancies. The formulation and the use of Busulfex in bone marrow transplant and other conditions is covered by United States Patent numbers 5,430,057 and 5, 559,148.
Foreign patents are pending.
Orphan Medical, Inc. is dedicated to patients with inadequately treated or uncommon diseases. To that end, the Company acquires, develops, and markets products of high medical value within selected strategic therapeutic market segments. For more information or details concerning specific drugs or topics, try searching this web site . How To Find Drug Info page. I regret that I can't answer email questions, but your comments are always welcome.